Acadia Pharmaceuticals

ACAD

Market cap $4.24B

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2025 at 9:45 a.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia Pharmaceutical.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ACADIA Pharmaceuticals Inc. ( ACAD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Mark Schneyer - Executive VP & CFO Ponni Subbiah Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Okay. Good day, everybody.

Acadia's third-quarter earnings and revenues top forecasts as Nuplazid and Daybue sales power double-digit annual growth.

ACADIA Pharmaceuticals Inc. ( ACAD ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Albert Kildani Catherine Owen Adams - CEO & Director Thomas Garner - Executive VP & Chief Commercial Officer Elizabeth Thompson - Executive VP and Head of Research & Development Mark Schneyer - Executive VP & CFO Conference Call Participants Ritu Baral - TD Cowen, Research Division Yigal Nochomovitz - Citigroup Inc., Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Brian Abrahams - RBC Capital Markets, Research Division So Youn Shim - UBS Investment Bank, Research Division Samuel Beck - Deutsche Bank AG, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Sean Laaman - Morgan Stanley, Research Division Tazeen Ahmad - BofA Securities, Research Division Jack Allen - Robert W. Baird & Co. Incorporated, Research Division Julian Hung - Stifel Nicolaus Canada Inc., Research Division Basma Radwan Ibrahim - Leerink Partners LLC, Research Division Poorna Kannan - Needham & Company, LLC, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good day, ladies and gentlemen, and thank you for standing by.

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.2 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2025. “Acadia delivered another strong quarter, generating total revenue of $278.6 million,” said Catherine Owen Adams, Chief Executive Officer. “NUPLAZID achieved record sales of $177.5 million representing a significant inflection driven by an acceleration in new prescriptions. DAYBUE delivered $101.1 million in sales, driven by the expansion o.

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: UBS Global Healthcare Conference Fireside Chat: Monday, November 10, 2025 at 2:00 p.m. Eastern Time in Palm Beach Gardens, FL Jefferies Global Healthcare Conference in London Presentation: Tuesday, November 18, 2025 at 8:30 a.m. Greenwich Mean Time in London Live webcasts of each will be accessible on the company's website, acadia.com, under the i.